CVD-2102

N/A

Report date: 2025/01/26 18:09:02

Base Information

Drug NameCVD-2102
Drug Alias Nameantimicrobial peptide P9 derivative (Guangzhou Xiangxue Pharmaceutical/Hangzhou Converd)CVD-2102
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsRespirovirus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesGuangzhou Xiangxue Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHangzhou Converd Co LtdGuangzhou Xiangxue Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsRespirovirus Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A